These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29737219)

  • 1. Use of acalabrutinib in patients with mantle cell lymphoma.
    Awan FT; Jurczak W
    Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acalabrutinib for adults with mantle cell lymphoma.
    Jurczak W; Długosz-Danecka M; Wang M
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
    Bond DA; Maddocks KJ
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):e184. PubMed ID: 30681658
    [No Abstract]   [Full Text] [Related]  

  • 7. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
    Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
    Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
    [No Abstract]   [Full Text] [Related]  

  • 9. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
    Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
    Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
    Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
    Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
    Hanna KS; Campbell M; Husak A; Sturm S
    J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
    Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
    Owen RG; McCarthy H; Rule S; D'Sa S; Thomas SK; Tournilhac O; Forconi F; Kersten MJ; Zinzani PL; Iyengar S; Kothari J; Minnema MC; Kastritis E; Aurran-Schleinitz T; Cheson BD; Walter H; Greenwald D; Chen DY; Frigault MM; Hamdy A; Izumi R; Patel P; Wei H; Lee SK; Mittag D; Furman RR
    Lancet Haematol; 2020 Feb; 7(2):e112-e121. PubMed ID: 31866281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.